Cipla Limited is an Indian multinational pharmaceutical company, headquartered in Mumbai, India. Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions.[5] As of 17 September 2014, its market capitalisation was ₹49,611.58 crore (equivalent to ₹530 billion or US$7.5 billion in 2019), making it India’s 42nd largest publicly traded company by market value.[6][7][8] On 23 April 2019, Cipla appointed Dr. Raju Mistry as Global Chief People Office. It was founded by Khwaja Abdul Hamied as ‘The Chemical, Industrial & Pharmaceutical Laboratories’ in 1935 in Mumbai.[10][11] The name of the company was changed to ‘Cipla Limited’ on 20 July 1984.[11] In the year 1985, the US FDA approved the company’s bulk drug manufacturing facilities.[12] Led by the founder’s son Yusuf Hamied, a Cambridge-educated chemist, the company provided generic AIDS and other drugs to treat poor people in the developing world.[13] In 1995, Cipla launched Deferiprone, the world’s first oral iron chelator.[10] In 2001, Cipla offered medicines (antiretrovirals) for HIV treatment at a fractional cost (less than $350 per year per patient) . In 2013 Cipla acquired the South African company Cipla-Medpro, kept it as a subsidiary, and changed its name to Cipla Medpro South Africa Limited.[15][16] At the time of the acquisition Cipla-Medpro had been a distribution partner for Cipla and was South Africa’s third biggest pharmaceutical company.[15] The company had been founded in 2002 and was known as Enaleni Pharmaceuticals Ltd.[17] In 2005, Enaleni bought all the shares of Medpro, which had been a joint venture between Cipla and Medpro Pharmaceuticals, a South African generics company,[18] and in 2008 it changed its name to
Script Name –CIPLA
Expire Date-AUGUST
Buy Price –931
Profit Target-950
Stop Loss-920
Call Duration-CARRY FORWARD
Disclaimer : Trading in the stock market, currency, or commodity markets is risky and has the potential to lose money. –Atal Trade Effort calls you after analyzing all aspects of all stocks. Investing is a personal matter. However, only one. The risk of loss in trading and investment in Securities markets including Equities, Derivatives, commodities, and Currency can be substantial. All products that carry a substantial risk of loss up to your invested capital. It May not be suitable for everyone. You should therefore carefully consider whether such trading is suitable for you in light of your financial condition. You invest a portion of your total money that will not be affected by the loss. Never put all your money into trading and never borrow money for the business
November 18, 2021
November 18, 2021
November 18, 2021
November 18, 2021
November 18, 2021
November 18, 2021
Leave a Reply